Overview
- Editors:
-
-
Mark R. Brann
-
Molecular Neuropharmacology Section Department of Psychiatry College of Medicine, University of Vermont, Burlington, USA
Access this book
Other ways to access
Table of contents (11 chapters)
-
Front Matter
Pages i-xvii
-
- Nicholas J. P. Ryba, Matthew D. Hall, John B. C. Findlay
Pages 1-30
-
- Brian O’Dowd, Sheila Collins, Michel Bouvier, Marc G. Caron, Robert J. Lefkowitz
Pages 31-61
-
- Catherine D. Strader, Richard A. F. Dixon
Pages 62-75
-
- John W. Regan, Susanna Cotecchia
Pages 76-112
-
- John R. Raymond, Salah El Mestikawy, Annick Fargin
Pages 113-141
-
- Hyman B. Niznik, Roger K. Sunahara, Hubert H. M. Van Tol, Philip Seeman, David M. Weiner, Tom M. Stormann et al.
Pages 142-159
-
- Olivier Civelli, James Bunzow, Paul Albert, Hubert H. M. Van Tol, David Grandy
Pages 160-169
-
- S. V. Penelope Jones, Allan I. Levey, David M. Weiner, John Ellis, Elizabeth Novotny, Shua-Hua Yu et al.
Pages 170-197
-
- David R. Poyner, Michael R. Hanley
Pages 198-232
-
-
- Allen M. Spiegel, Paul K. Goldsmith, William F. Simonds, Teresa Jones, Kevin Rossiter, Cecilia G. Unson
Pages 270-298
-
Back Matter
Pages 299-326
About this book
LESLIE L. IVERSEN The present series of volumes is well timed, as the impact of molecular genetics on pharmacology has been profound, and a comprehensive review of the rapid advances of the past decade is much needed. Since the pioneering work of Dale, Ariens, and others in the early years of this century, much of pharmacology has been founded on the concept of receptors. To begin with, the receptor was conceived of as a "black box," which recognized and transduced the biological effects of neurotransmit ters, hormones, or other biological messengers-and which could also represent a target for man-made drugs. It is only in the last two decades that "molecular pharmacology" has blossomed, first with the advent of radioligand binding techniques and second messenger studies which greatly facilitated the biochemical study of drug-receptor interactions, and latterly with increasing knowledge of the molecular architecture of the receptor proteins themselves. This started with the traditional biochemical approach of isolating and purifying the receptor molecules. This proved to be a task of immense technical difficulty because of the low density of receptors in most biological source tissues, although there were some notable successes, e. g. , the purification of the nicotinic acetylcholine receptor from the electric organ of Torpedo. It was the ap plication of molecular genetics technology during the 1980s, however, which really accelerated progress in this field.
Editors and Affiliations
-
Molecular Neuropharmacology Section Department of Psychiatry College of Medicine, University of Vermont, Burlington, USA
Mark R. Brann
